In this study we found that the expression of DR5 (TRAILR2, TNFRSF10B) presented a malignant phenotype as an independent risk factor for poor prognosis in gastric cancer patients, which was different from DR4 (TRAILR1, TNFRSF10A). Here, TNFRSF10B is linked to gastric cancer.